Our Company

Our mission is to develop innovative cellular therapies to transform cancer treatment worldwide​.

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT’s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors.ICT has achieved promising proof-of-concept clinical results in metastasis solid cancers, such as colorectal cancer and prostate cancer.

Corporate Milestones

Founded to develop iPSC (induced pluripotent stem cells) technology

  • Established a well-trained R&D team in cell engineering
  • Experienced in sophisticated technologies, including iPSC, lentiviral vectors, and gene editing

Shifted to CAR-T cells technology

  • ICT’s first CAR-T product to treat ALL in a human IRB1 approved trial with 39 patients achieved 85% CR in 2015
  • Accumulated experiences in liquid tumor CAR-T that helped development of solid tumor CAR-T technology platform

Focused on solid tumor CAR-T

  • Rapid CoupledCAR® technology improvements after the first solid tumor trial started in 2017
  • Objective responses achieved in colorectal cancer from 2019

Transformed to a US focused company

  • Established operations in the U.S. in 2018 followed by opening of Global HQ in Rockville, MD in 2019
  • Obtained U.S. IND clearance for CoupledCAR® colorectal cancer program in August 2021

Conducting a U.S. registered clinical trial and preparing for commercialization in the U.S.

  • In August 2021, GCC19CART, a product for the treatment of advanced colorectal cancer, received IND approval from the U.S. FDA

The clinical trials of GCC19CART initiated in the United States

  • In April 2022, GCC19CART was granted Fast Track designation by the U.S. FDA, making it eligible for Accelerated Approval and Priority Review in the future, which will expedite the clinical trial and market approval process
  • In July 2022, the Phase I clinical trial of GCC19CART was initiated in the U.S. to validate and replicate the results obtained from the domestic clinical trials
  • Currently, the U.S. clinical trial CARAPIA-1 is ongoing, with the clinical trial identifier: NCT05319314
Start Typing